NATURAL KILLER CELLS MARKET ANALYSIS

Market News

Key Developments

1. Key players in the market are focused on various business strategies research and development, in order gain competitive edge in the market. For instance, in June 2019, NantKwest, a U.S.-based immunotherapy company, announced the U.S. Food and Drug Administration (FDA) clearance for the company’s PD-L1 t-haNK investigational new drug application (IND). The program is now transitioned to first-in-human clinical trial in patients with locally or advanced metastatic solid cancers.
2. Key players in the market are involved in various business strategies such as partnership and collaboration, in order provide novel products in the market. For instance, in March 2019, Phio Pharmaceuticals Corp., a U.S.-based pharmaceutical company, and Glycosystem Therapeutics BV, a Dutch biotech company, collaborated to explore potential synergies of using Phio’s self-delivering RNAi technology in combination with Glycosystem’s natural killer cell technology oNKord. This collaboration is done to develop cellular immunotherapies for cancer treatment.
3. Major companies in the global market are involved in growth strategies such as gaining grants from various institutes, in order develop novel products. For instance, in December 2018, Glycostem and Enpicom received a research subsidiary of undisclosed amount from the Dutch MIT Zuid research and development subsidy scheme. The companies are planning to use the funds to develop technology to predict the outcome of NK-Cell-based immunotherapy in patients with solid tumors.